Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2011-08-23 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 23, 2011. It announces that TapImmune Inc. will sponsor a Phase I clinical trial following FDA IND approval. The content focuses on a regulatory disclosure about a clinical trial initiation and related agreements, not on financial results, management changes, or detailed financial data. The document is relatively short (4835 characters) and primarily serves as a regulatory disclosure of a material event. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-08-23 English
Interim / Quarterly Report 2011
Interim / Quarterly Report Q2 2011
2011-08-22 English
FORM NT 10-Q
Regulatory Filings Classification · 95% confidence The document is a Form 12B-25, which is a Notification of Late Filing for a Form 10-Q quarterly report. It states that the quarterly report for the period ended June 30, 2011, has not been filed on time due to administrative and accountant delays. The document does not contain the actual financial data or the quarterly report itself, but rather a notification about the delay in filing. The document length is 3076 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification should be classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing, not the report itself.
2011-08-15 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from TapImmune Inc. to the SEC regarding comments and responses about the company's 2010 Form 10-K and other periodic reports (10-Qs). It discusses restatements, accounting treatments, valuation models, and disclosures related to the annual and quarterly financial reports. The letter references specific SEC comment letters and responses, and the company’s intention to amend and restate prior filings. This is not the annual report itself but a regulatory correspondence about the annual report and related filings. The document is lengthy (over 12,000 characters) and contains substantive discussion of financial reporting issues, but it is not the report itself. It is a regulatory correspondence letter related to SEC review of filings, which fits best under Regulatory Filings (RNS) as it does not contain the full annual report or financial statements but is a communication about them.
2011-07-14 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from TapImmune Inc. to the SEC referencing multiple filings: 2009 and 2010 Form 10-Ks and a 2010 Form 10-Q. It discusses intentions to provide revised drafts of these reports and other periodic filings. The document is short (1256 characters) and is a response to a comment letter, not the actual financial reports themselves. It does not contain financial data or the reports but is a regulatory communication. Therefore, it fits the category of Regulatory Filings (RNS) as a correspondence related to filings rather than the filings themselves.
2011-07-12 English
Regulatory Filings 2011
Regulatory Filings
2011-06-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.